spacer
home > ebr > summer 2004 > the declaration of helsinki: protecting patient rights in biomedical research drug discovery technologies
PUBLICATIONS
European Biopharmaceutical Review

The Declaration of Helsinki: Protecting Patient Rights in Biomedical Research Drug Discovery Technologies

The Declaration of Helsinki is the world's most widely recognised source of ethical guidance for biomedical research. Since its adoption in 1964, it has become the pre-eminent ethical guidance on health care research. Adherence to it is required by the World Health Organization and by many national governments, who refer to its provisions in their legislation. Scientists are often criticised for carrying out research in developing countries without following the Declaration, and some organisations and companies sponsoring research request that researchers receiving funding abide by its requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Delon Human, Secretary General of the World Medical Association

Dr Delon Human has been Secretary General of the WMA since 1998. He is a former family physician from Pretoria, South Africa and a past president of a branch of the Medical Association of South Africa. He qualified as a family practitioner in 1985 and spent some time at the John Radcliffe Hospital in Oxford, England, conducting research in paediatric endocrinology. He then gained two further Masters degrees in Family Medicine and a Diploma in Child Health. In addition to his medical qualifications, Dr Human has also obtained an MBA from the European Business School.

spacer
Dr Delon Human
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth

TBM Consulting Group

The pharmaceutical industry faces countless challenges: patent expirations, weak product development pipelines, downward pricing pressure and an increasingly burdensome regulatory environment. The most important question for companies is now “How can we position ourselves optimally to be successful in the long term?” Some pharmaceutical companies used the economic downturn in 2009 to embrace measures in the fields of cost reduction and efficiency increases, which can be implemented at short notice. The continuous and consistent implementation of sustainable measures that guarantee stability and form the basis for future growth was not necessarily paramount within this.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement